• Valemetostat in Relapsed/Refractory Lymphoma

  2026-10-14

  A literature-focused analysis of the first-in-human phase 1 study of Valemetostat (DS-3201), emphasizing its dual EZH1/EZH2 rationale, reported activity, safety findings, and the limits of interpreting single-arm data across biologically diverse lymphomas.

• EZH2 Signaling in Melanoma Drug Resistance

  2026-10-14

  A 2026 study links eIF4F-inhibitor resistance in BRAFV600E melanoma cells to compensatory ERK1/2–EZH2 and AKT1–eIF4E signaling. Its findings support a mechanistic rationale for combined pathway blockade, but the evidence remains preclinical and does not establish that EPZ-6438 was used or that the strategy is clinically effective.

• Valemetostat in Epigenetic Lymphoma Research

  2026-10-13

  Valemetostat (DS-3201) is described by APExBIO as a selective EZH1/EZH2-directed compound, but the supplied research paper does not test it. The cited acute lymphoblastic leukaemia study instead links MIR9-family hypermethylation with reduced MIR9 expression, increased FGFR1 and CDK6 activity, and poorer clinical outcomes. These findings provide epigenetic context rather than direct evidence for Valemetostat in ALL or for its use in relapsed/refractory follicular lymphoma or diffuse large B-cell lymphoma.

• Catalpol and Triptolide-Induced Liver Injury

  2026-10-13

  A 2024 study used complementary mouse and cell models to examine whether catalpol can mitigate triptolide-associated liver injury through SIRT1/HIF-1α regulation. The reported findings support a mechanistic relationship between SIRT1 activity, hepatic energy metabolism, mitochondrial dysfunction and oxidative stress, but the evidence remains preclinical and does not establish clinical efficacy or safety in people.

• PM2.5, Gm16410 and Lung EndMT

  2026-10-12

  A source-grounded overview of a mouse and cell study linking PM2.5 exposure with endothelial–mesenchymal transition through TGF-β1/Smad3 signaling, while clarifying what the findings do—and do not—show about SB 431542.

• Indomethacin: Identity and Evidence Scope

  2026-10-12

  Indomethacin is documented by the APExBIO product listing as a nonsteroidal anti-inflammatory drug with reported cyclooxygenase-related, PPAR-associated, and membrane-signaling research relevance. No matched primary paper was available, so these descriptions should be treated as product-level claims rather than validated study findings.

• CTCF, Centromere Function, and Mitotic Fidelity

  2026-10-10

  The reference study uses rapid, inducible CTCF depletion to show that CTCF supports centromere performance, accurate mitosis, and post-mitotic nuclear morphology. Its evidence separates CTCF-dependent centromere architecture from a primary defect in CENP-E recruitment, refining how chromosome alignment regulation can be interpreted in cell biology and cancer research.

• Alkaline Phosphatase Substrate Test Kit Overview

  2026-10-09

  The APExBIO Alkaline Phosphatase Substrate Test Kit (SKU K4151) is a BCIP/NBT chromogenic product described for visual alkaline phosphatase activity detection. No matched paper evidence was supplied, so application-specific performance remains unverified.

• Ranolazine: Metabolic Context for Liver Research

  2026-10-09

  Ranolazine is best known as an anti-ischemic agent, but its metabolic pharmacology offers a useful framework for interpreting liver-cell signaling studies. This article connects cardiac energy metabolism with the HBsAg–TBK1–autophagy findings while clearly separating established evidence from hypothesis.

• BIBP 3226 Trifluoroacetate: Evidence Guide

  2026-10-08

  BIBP 3226 trifluoroacetate is a supplier-described non-peptide antagonist for NPY Y1 and NPFF receptor research. Its reported binding values support target-engagement studies, while recent cardiac evidence links the leptin–NPY–Y1R axis to arrhythmia without establishing that BIBP 3226 was used in that study.

• L-Alanyl-L-Glutamine Product Overview

  2026-10-08

  L-Alanyl-L-glutamine, also known as an L-Ala-L-Gln dipeptide, is a synthetic, water-soluble dipeptide composed of L-alanine and L-glutamine. APExBIO lists its identity, formulation specifications, and a gastrointestinal nutritional research scope, but no matched paper evidence was provided to validate biological performance.

• Octyl-α-ketoglutarate in HIF-1α Research

  2026-10-07

  This overview examines Octyl-α-ketoglutarate as a research tool for studying α-ketoglutarate-dependent signaling, HIF-1α regulation, and cancer metabolism. It compares supplier-described properties with findings from a 2024 colorectal cancer study and defines the evidence limits of applying that work to IDH and hypoxia research.

• Nanozymes Target Intramacrophage Bacteria in CRC

  2026-10-07

  Yu and colleagues report a self-activatable polymeric nanozyme designed to eliminate intracellular Fusobacterium nucleatum in colorectal cancer-associated macrophages and remodel an immunosuppressive tumor microenvironment. The study links macrophage-directed delivery, peroxide-responsive activation, autophagy-associated compartmentalization, and CD47 blockade, while its evidence remains primarily preclinical and model-dependent.

• Capsaicin, TRPV1, and Sensory Signaling

  2026-10-06

  Capsaicin, also called (E)-Capsaicin, is best understood as a context-dependent TRPV1 probe with additional reported KDM1A/LSD1 activity. Recent work links 20-HETE, sensitized MrgprA3+ neurons, and altered itch–pain coding in chronic dermatitis, while evidence for cancer and broader therapeutic applications remains more model-dependent.

• ATG4B, Energy Deficiency, and AML DNA Repair

  2026-10-06

  A 2025 Advanced Science study identifies energy deficiency-induced nuclear translocation of ATG4B as a mechanism that interferes with PRMT1-dependent MRE11 methylation and DNA repair in acute myeloid leukemia. The work connects metabolic stress with genomic instability across cellular, mouse, and patient-derived models, while its therapeutic implications remain preclinical and require validation in broader AML settings.

8550 records 1/570 page Next 12345 下5页 Last page